A growing body of researchers around the world is working to mount an aggressive and sustained response to the COVID-19 pandemic. By building on past successes and harnessing insights from current efforts, the scientific community will be better able to detect and characterize pathogens, identify treatments, and prepare for future outbreaks.

A comprehensive multi-omic approach is required to understand the complex biological mechanisms involved in SARS-CoV-2 infection, improve the ability to detect and characterize the virus, and assess the subsequent impact on the immune system and the response to therapeutic intervention. Fluidigm microfluidics-based genomic analysis tools and mass cytometry capabilities for highly multiplexed immune cell quantitation are uniquely enabling for virus detection and immune profiling of individuals, and will be increasingly important to government and medical institutions. In this presentation, we will describe our genomic analysis solutions for PCR- and NGS-based applications leveraging the benefits of nanoliter-scale automated microfluidics technology. We will also present the best-in-class immune profiling and monitoring capabilities of mass cytometry, powered by our CyTOF® technology. Our discussion will reflect the use of these tools in research efforts currently underway.

For Research Use Only. Not for use in diagnostic procedures.